Latest & greatest articles for atorvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atorvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atorvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atorvastatin

81. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis 12686036 2003 04 10 2003 04 22 2015 11 19 0140-6736 361 9364 2003 Apr 05 Lancet (London, England) Lancet Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol (...) with at least three other cardiovascular risk factors) randomised to one of two antihypertensive regimens in the Anglo-Scandinavian Cardiac Outcomes Trial, 10305 with non-fasting total cholesterol concentrations 6.5 mmol/L or less were randomly assigned additional atorvastatin 10 mg or placebo. These patients formed the lipid-lowering arm of the study. We planned follow-up for an average of 5 years, the primary endpoint being non-fatal myocardial infarction and fatal CHD. Data were analysed by intention

Lancet2003

82. [Cost-effectiveness analysis of atorvastatin versus simvastatin as lipid lowering treatment for primary care patients with hypercholesterolaemia]

[Cost-effectiveness analysis of atorvastatin versus simvastatin as lipid lowering treatment for primary care patients with hypercholesterolaemia] Analisis coste-efectividad de atorvastatina frente a simvastatina como tratamiento hipolipemiante en pacientes hipercolesterolemicos en atencion primaria [Cost-effectiveness analysis of atorvastatin versus simvastatin as lipid lowering treatment for primary care patients with hypercholesterolaemia] Analisis coste-efectividad de atorvastatina frente (...) a simvastatina como tratamiento hipolipemiante en pacientes hipercolesterolemicos en atencion primaria [Cost-effectiveness analysis of atorvastatin versus simvastatin as lipid lowering treatment for primary care patients with hypercholesterolaemia] Tarraga Lopez P J, Celada Rodriguez A, Cerdan Oliver M, Solera Albero J, Ocana Lopez J M, de Miguel Clave J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary

NHS Economic Evaluation Database.2001

83. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. 11277825 2001 03 30 2001 04 19 2016 10 17 0098-7484 285 13 2001 Apr 04 JAMA JAMA Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. 1711-8 Patients experience the highest rate of death and recurrent ischemic events during the early period after an acute coronary syndrome (...) , but it is not known whether early initiation of treatment with a statin can reduce the occurrence of these early events. To determine whether treatment with atorvastatin, 80 mg/d, initiated 24 to 96 hours after an acute coronary syndrome, reduces death and nonfatal ischemic events. A randomized, double-blind trial conducted from May 1997 to September 1999, with follow-up through 16 weeks at 122 clinical centers in Europe, North America, South Africa, and Australasia. A total of 3086 adults aged 18 years or older

JAMA2001

84. Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia

Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia (...) elemental calcium) three times per day with meals) plus atorvastatin calcium (10mg once daily) in the reduction of lipoprotein (LDL) in the treatment of dyslipidemia and hyperphosphatemia for patients with chronic renal insufficiency (CRI). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with CRI, but no cardiovascular disease, with moderate hyperphosphatemia (plasma phosphorus 6.0-7.5 mg/dl) and a borderline high

NHS Economic Evaluation Database.2000

85. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. 10395630 1999 07 13 1999 07 13 2015 11 19 0028-4793 341 2 1999 Jul 08 The New England journal of medicine N. Engl. J. Med. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. 70-6 Percutaneous coronary revascularization is widely used (...) per liter) who were referred for percutaneous revascularization. We randomly assigned the patients either to receive medical treatment with atorvastatin, at 80 mg per day (164 patients), or to undergo the recommended percutaneous revascularization procedure (angioplasty) followed by usual care, which could include lipid-lowering treatment (177 patients). The follow-up period was 18 months. Twenty-two (13 percent) of the patients who received aggressive lipid-lowering treatment with atorvastatin

NEJM1999

86. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias

Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias Yee H S, Fong N T Authors' objectives To assess the efficacy and safety of atorvastatin in the treatment of dyslipidemias. Searching MEDLINE (January 1960 to April 1998) and Current Contents were searched for articles published (...) in the English language. Additional references were sought from bibliographies of identified studies and unpublished data from manufacturers. Study selection Study designs of evaluations included in the review The authors selected open and controlled human and animal clinical trials on the pharmacology, pharmacokinetics, therapeutic use and adverse effects of atorvastatin, limited to information on human clinical trials. Randomised clinical trials (RCTs) and open clinical trials that evaluated atorvastatin

DARE.1998

87. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. 8531308 1996 02 01 1996 02 01 2016 10 17 0098-7484 275 2 1996 Jan 10 JAMA JAMA Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. 128-33 To assess the lipid-lowering effect of atorvastatin (a new 3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitor) on levels of serum triglycerides and other lipoprotein (...) fractions in patients with primary hypertriglyceridemia, determine if atorvastatin causes a redistribution of triglycerides in various lipoprotein fractions, and assess its safety by reporting adverse events and clinical laboratory measurements. Randomized double-blind, placebo-controlled, parallel-group, multicenter trial. Community- and university-based research centers. A total of 56 patients (aged 26 to 74 years) with a mean baseline triglyceride level of 6.80 mmol/L (603.3 mg/dL) and a mean

JAMA1996